Committed to Science and Teamwork
MIRA brings together leading scientists, doctors, researchers and business executives.
Mira and the Future of Neuroscience Innovation
MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. MIRA holds the exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a novel, patent-pending oral ketamine analog under investigation to treat neuropathic pain (NP), treatment-resistant depression (TRD), major depressive disorder with suicidal ideation (MDD-SI), and post-traumatic stress disorder (PTSD).
MIRA's novel oral pharmaceutical marijuana analog, MIRA-55, is currently under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. If approved by the FDA, MIRA-55 could mark a significant advancement in addressing various neuropsychiatric, inflammatory, and neurologic diseases and disorders.
The U.S. Drug Enforcement Administration's scientific review concluded that both Ketamir-2 and MIRA-55 would not be considered controlled substances or listed chemicals under the Controlled Substances Act and its governing regulations.
Introducing Ketamir
Key Flagship Drug Candidate
Our lead drug candidate and a novel, patent-pending ketamine analog designed with enhanced gastrointestinal bioavailability. Ketamir is currently under investigation for its potential to address neuropathic pain effectively, targeting a significant unmet need in pain management. In addition, Ketamir aims to provide ultra-rapid antidepressant effects through oral delivery, offering hope for individuals suffering from treatment-resistant depression (TRD) and major depressive disorder with suicidal ideation (MDD-SI).
Learn About KetamirIntroducing MIRA-55
Our Secondary Key Drug
Presenting MIRA-55, an innovative candidate aimed at advancing the treatment of neuropsychiatric, inflammatory, and neurologic diseases and disorders. MIRA-55 leverages the therapeutic potential of marijuana through a single molecule that targets the body’s endocannabinoid system.
Learn About MIRA-55Meet Our Scientific Advisory Board
We continue to add clinical and scientific talent to our research and discovery team to evaluate our research, advise us on new processes and support our science.
View Our Scientific Advisory Board